含贝伐珠单抗单药方案在老年铂耐药复发性卵巢癌患者中的安全性和有效性:随机III期AURELIA试验的亚组分析
AURELIA试验的事后探索性分析按年龄<65岁与≥65岁分层,评估含贝伐珠单抗方案在铂耐药复发性卵巢癌中的疗效、安全性和患者报告结局。≥65岁患者133例(37%),贝伐珠单抗带来的无进展生存获益幅度在两个年龄组相似(≥65岁风险比0.44,95%CI 0.31-0.64;<65岁风险比0.49,95%CI 0.37-0.64;治疗-年龄交互作用p=0.58),缓解率改善也相似。≥3级高血压在贝伐珠单抗组更常见,老年患者中更常见;推荐仔细监测。
要点
- ≥65岁患者133例(37%),贝伐珠单抗的无进展生存获益与<65岁患者相似(风险比0.44 vs 0.49,交互作用p=0.58)。
- ≥3级高血压在贝伐珠单抗组较单纯化疗更常见,且老年患者较年轻患者更常见,与治疗无关。
- 老年患者中未观察到贝伐珠单抗其他特定不良事件(包括静脉血栓栓塞事件)增多,推荐仔细监测。
核心结论
- 探索性分析显示,贝伐珠单抗在老年和年轻患者中带来的无进展生存和缓解率改善一致。
- ≥3级高血压在老年贝伐珠单抗治疗患者中更常见,推荐仔细监测。
- 总体而言,含贝伐珠单抗方案在≥65岁选定人群中耐受良好,提示有利的获益:风险特征。
- 需要老年评估来改进老年患者的选择,以识别可能从含贝伐珠单抗方案中获得症状和生活质量改善的患者。
研究设计与样本
- AURELIA试验的事后探索性分析,患者按研究者选择的单药化疗 alone 或联合贝伐珠单抗随机分组。
- 按年龄<65岁与≥65岁进行分层分析,评估疗效、安全性和患者报告结局。
- ≥65岁患者133例(37%)。
主要发现
- ≥65岁患者基线高血压更常见,腹水较<65岁患者少见。
- 贝伐珠单抗的无进展生存获益幅度在≥65岁与<65岁患者相似:风险比0.44(95%CI 0.31-0.64) vs 0.49(95%CI 0.37-0.64),治疗-年龄交互作用p=0.58。
- 缓解率改善在两个年龄组相似。
- ≥3级高血压在贝伐珠单抗组较单纯化疗更常见(两个亚组均如此),且老年患者较年轻患者更常见,与治疗无关。
- 老年患者中未观察到贝伐珠单抗其他特定不良事件(包括静脉血栓栓塞事件)增多。
关键数值与推荐
- ≥65岁患者贝伐珠单抗的无进展生存风险比0.44(95%CI 0.31-0.64)。
- <65岁患者贝伐珠单抗的无进展生存风险比0.49(95%CI 0.37-0.64)。
- 治疗-年龄交互作用p=0.58。
临床怎么用
- 作者推荐对老年贝伐珠单抗治疗患者仔细监测≥3级高血压。
- 作者认为需要老年评估来改进老年患者的选择,以识别可能从含贝伐珠单抗方案中获得症状和生活质量改善的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The AURELIA trial demonstrated significantly improved progression-free survival (PFS) with bevacizumab added to chemotherapy for platinum-resistant ovarian cancer (PROC). METHODS: Patients with PROC were randomised to receive investigator-selected single-agent chemotherapy alone or with bevacizumab. Post-hoc exploratory analyses assessed efficacy, safety and patient-reported outcomes according to age <65 versus ≥65years. RESULTS: In the 133 patients (37%) aged ≥65years, baseline hypertension was more frequent and ascites was less common than in patients <65years. The magnitude of PFS benefit from bevacizumab was similar in patients ≥65 versus <65years (hazard ratio 0.44 [95% CI, 0.31-0.64] versus 0.49 [95% CI, 0.37-0.64], respectively, treatment-age interaction p=0.58), with similar improvements in response rates. Grade≥3 hypertension was more common with bevacizumab than chemotherapy alone in both subgroups, and more common in older than younger patients irrespective of treatment. However, there was no excess of other adverse events of specific interest for bevacizumab, including venous thromboembolic events, in older patients. More patients receiving bevacizumab in the younger but not the older subgroup showed improved gastrointestinal/abdominal symptoms. CONCLUSION: In exploratory analyses, PFS and response rate improvement with bevacizumab were consistent in older and younger patients. Grade≥3 hypertension was more common in elderly bevacizumab-treated patients; careful monitoring is recommended. Overall, bevacizumab-containing therapy was well tolerated in a selected population aged ≥65years, suggesting a favourable benefit:risk profile. However, geriatric assessments are needed to improve selection of elderly patients potentially gaining symptom and quality of life improvements from bevacizumab-containing therapy. CLINICAL TRIALS REGISTRATION: ClinicalTrials.govNCT00976911.
引用
- Sorio R, Roemer-Becuwe C, Hilpert F, et al. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2016. PMID: 27871723. doi:10.1016/j.ygyno.2016.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。